title: Current topics of S-1 at the 74th Japanese Gastric Cancer Congress.
abstract: S-1 (TS-1)-related studies presented at the 74th Japanese Gastric Cancer Congress are reviewed. Of the papers presented at this conference, 35 were related to S-1. In the panel discussion on the therapeutic significance of oral fluoropyrimidines in gastric cancer, 9 papers were related to S-1 (sensitivities to oral fluoropyrimidines, 2 papers; clinical results of treatment with S-1, 5 papers; and combination therapy with S-1, 2 papers). In the general presentations, there were 26 papers on S-1 related-subjects (clinical studies or clinical practice of S-1, 12 papers; case reports, 3 papers; basic studies on animal models of peritoneal metastasis, 2 papers; and combination therapy with S-1, 9 papers). Several studies showed that S-1 was basically as effective against tumors in postmarketing surveillance in clinical practice as in phase II studies at the time of its development, including a report of a patient with complete response to S-1. Some reports suggested the possibility of using S-1 in neoadjuvant chemotherapy and postoperative adjuvant chemotherapy. The usefulness of S-1 in combination chemotherapy was also suggested in several reports. These results indicate that S-1 is a key drug that can be used in first-line treatment of gastric cancer. It will be necessary to accumulate evidence based on data from clinical trials and clinical applications in the future.
authors.affiliation: Department of Chemotherapy, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-5677, Japan.
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Sasaki
mesh_terms: D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil